SALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D.
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service